Key result
Helix-fixation leadless pacemaker implantation triggers sustained ventricular arrhythmia in undiagnosed CAD, resolving after retrieval.
Why the study?
Leadless pacing with the Aveir single-chamber leadless pacemaker uses a unique helix-fixation mechanism and its safety profile requires further characterization.
Case Report (n=1)
Alerts to VA risk during helix-fixation leadless pacemaker implantation in undiagnosed CAD; leaves open whether this is device-specific or class effect.
Leadless pacing provides a favorable safety and efficacy profile in selected patients compared with traditional transvenous pacemakers.1 The Aveir™ single-chamber (VR) leadless pacemaker (LP) (Abbott Laboratories, Chicago, IL) was recently approved by the U.S. Food and Drug Administration in April 2022. It uses a unique helix-fixation mechanism and is the only commercially available leadless pacemaker designed to be retrievable.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2023) conducted a case report in Tachy-brady syndrome and ventricular arrhythmia (n=1). Aveir VR helix-fixation leadless pacemaker was evaluated. Implantation of a helix-fixation leadless pacemaker triggered sustained ventricular arrhythmia in the presence of previously undiagnosed 3-vessel coronary artery disease, which resolved upon device retrieval.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: